Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.45 |
| ▸ | EIF4E | P06730 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | CTSC | P53634 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 9/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24958907 | 0.81 | PIM1 (0.53) | BRD4EIF4EMKNK1MKNK2KIT | |
| SCHEMBL24958882 | 0.80 | JAK2 (0.48) | BRD4EIF4EMKNK1MKNK2KIT | |
| SCHEMBL17794957 | 0.78 | CHRM1 (0.59) | CHRM1CHRM5NAAA | |
| SCHEMBL19155042 | 0.75 | CTSC (0.55) | JAK2CTSKCTSCCHRM1 | |
| SCHEMBL19155346 | 0.75 | CTSC (0.55) | JAK2CTSKCTSCCHRM1 | |
| SCHEMBL19155068 | 0.75 | CTSC (0.55) | JAK2CTSKCTSCCHRM1 | |
| SCHEMBL22643243 | 0.73 | CTSK (0.46) | CTSKCTSCCHRM1CHRM5NAAA | |
| SCHEMBL19155147 | 0.73 | CTSC (0.55) | BRD4CTSKCTSCCREBBPCHRM1 | |
| SCHEMBL19155286 | 0.71 | CTSK (0.48) | BRD4CTSKCTSCCREBBPCHRM1 | |
| SCHEMBL24958696 | 0.71 | SOST (0.43) | BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | BRD4 1246/4885EIF4E 1225/4885MKNK1 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.